Stocks Health care RANI
NASDAQ · Health careRani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. brought in $4.9M of revenue over the twelve months to June 30, 2026, up 306.4% from a year earlier. It posted a net loss of $30.1M. In fiscal 2025 capital spending exceeded operating cash flow by $18.8M. At June 30, 2026 it held $4.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Rani Therapeutics Holdings, Inc.
- Net worth
- Rani Therapeutics Holdings, Inc. has a market value (market cap) of $80.1M at the latest share price, and shareholders' equity of $39.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $1.6M (+58.9% year on year), with a net loss of $29.7M. Over the 12 months to June 30, 2026: revenue $4.9M, net loss $30.1M.
- Cash flow
- In fiscal 2025 operations used $18.7M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Rani Therapeutics Holdings, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
What Rani Therapeutics Holdings, Inc. does
Rani Therapeutics Holdings, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker RANI.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $1.6M | -$29.7M | -$0.45 | -$18.8M |
| 2024 | $1M | -$30M | -$1.05 | -$35.8M |
| 2023 | $0 | -$34M | -$1.33 | -$52.5M |
| 2022 | $0 | -$30.6M | -$1.28 | -$48.1M |
| 2021 | $2.7M | -$8.3M | -$0.43 | -$32.8M |
| 2021 | $462K | -$16.7M | n/a | -$16.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where RANI ranks in Health care
Latest SEC filings
What Rani Therapeutics Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026
- August 13, 2026
- August 4, 2026
- July 31, 2026Passive stake changed SCHEDULE 13G/A
- July 15, 2026
- June 30, 2026
- May 29, 2026
- May 28, 2026Activist stake changed SCHEDULE 13D/A
- May 27, 2026Other event 8-K
Insider trades
What the people running Rani Therapeutics Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 2 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 27, 2026 | Javadi AlirezaChief Technical Officer | Shares withheld for tax | 309 | $234.6 |
| September 27, 2026 | Imran TalatChief Executive Officer, Director | Shares withheld for tax | 7,928 | $6K |
| July 21, 2026 | Imran Mir ADirector, 10% owner | Bought | 36,000 | $24.8K |
| July 17, 2026 | Imran TalatChief Executive Officer, Director | Bought | 35,000 | $25.2K |
| June 27, 2026 | Imran TalatChief Executive Officer, Director | Shares withheld for tax | 7,927 | $5.9K |
| June 27, 2026 | Javadi AlirezaChief Technical Officer | Shares withheld for tax | 309 | $228.7 |
| March 27, 2026 | Imran TalatChief Executive Officer, Director | Shares withheld for tax | 9,099 | $7.4K |
| March 27, 2026 | Javadi AlirezaChief Technical Officer | Sold | 386 | $301.1 |
Who owns RANI
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Mir A Imran13D, may seek influence with 3 related filers | 22.1% | October 27, 2025 |
| Raymond Debbane13G, passive with 7 related filers | 9.99% | October 23, 2025 |
| AWM Investment Company, Inc.13G, passive | 9.9% | February 13, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 9.9% | August 14, 2026 |
| Srinivas Akkaraju13D, may seek influence with 4 related filers | 9.9% | May 28, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 67 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Samsara Biocapital, LLC | 10,369,159 | +1,869,159 |
| RA Capital Management, L.P. | 8,500,000 | 0 |
| AWM Investment Company, Inc. | 7,500,000 | +1,000,000 |
| Vanguard Capital Management LLC | 4,562,985 | -59,582 |
| Longaeva Partners L.P. | 2,329,459 | 0 |
| Polar Asset Management Partners Inc. | 2,318,542 | new |
| Siren, L.L.C. | 2,000,000 | 0 |
| Heights Capital Management, Inc | 934,580 | new |
| Geode Capital Management, LLC | 890,618 | -12,680 |
| Citadel Advisors LLC | 641,995 | new |
| Marshall Wace, Llp | 586,265 | new |
| Nan Fung Group Holdings Ltd | 493,584 | 0 |
| Jane Street Group, LLC | 485,899 | +320,300 |
| Vanguard Fiduciary Trust Co | 458,126 | +3,076 |
| Renaissance Technologies LLC | 430,737 | new |
| State Street Corp | 373,142 | 0 |
| BlackRock, Inc. | 342,113 | -214,776 |
| United Services Automobile Association | 302,743 | 0 |
| UBS Group AG | 297,270 | +70,047 |
| Kestra Private Wealth Services, LLC | 282,340 | +17,181 |
Insiders
3 insiders reported holding 2,590,213 shares in total, about $1.5M at the last price.
| Holder | Shares |
|---|---|
| Imran Mir ADirector, 10% owner | 2,119,334 |
| Imran TalatChief Executive Officer, Director | 461,808 |
| Javadi AlirezaChief Technical Officer | 9,071 |
Questions about RANI
What does Rani Therapeutics Holdings, Inc. do?
Rani Therapeutics Holdings, Inc. is a company in the Health care sector, listed on NASDAQ as RANI. Its shares trade on NASDAQ under the ticker RANI.
What is Rani Therapeutics Holdings, Inc.'s net worth?
Rani Therapeutics Holdings, Inc. has a market value (market cap) of $80.1M at the latest share price, and shareholders' equity of $39.2M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Rani Therapeutics Holdings, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $30.1M on revenue of $4.9M.
How much revenue does Rani Therapeutics Holdings, Inc. make?
Over the twelve months to June 30, 2026 Rani Therapeutics Holdings, Inc. reported revenue of $4.9M. That is 306.4% more than a year earlier.
When did Rani Therapeutics Holdings, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 29, 2026.
When is Rani Therapeutics Holdings, Inc.'s next earnings report?
Rani Therapeutics Holdings, Inc.'s next report was expected around November 5, 2026 and is not on file with the SEC yet.
Similar companies
Compare RANI with
Follow RANI
Get an email when Rani Therapeutics Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Rani Therapeutics Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.